Japan Clears Nine Drugs For Approval, But Only A New DPP-4 Is First Out The Gate
This article was originally published in PharmAsia News
Executive Summary
Despite MHLW's progress in cutting the drug lag, no drugs from a June 29 batch of approvals are first-to-market save for a DPP-4 from Mitsubishi Tanabe, which enters a crowded market.